arrow
S

Steven A. Feldman

Stanford University
H-index:51
Citation Count:2.4万
Views:0

Biography

No content for now.

Education

No content for now.

Work Experience

No content for now.

Honors & Awards

No content for now.

Performance of a modular robotic cluster matches skilled human operators for complex cell therapy manufacturing tasks

模块化机器人集群在复杂细胞治疗制造任务中的性能与熟练人类操作员相当

2026-08-010
OAAI
HUMANIZED ANTI-CAR ANTIBODIES AFFECT DURABLE RESPONSE TO GD2-CAR T-CELLS IN DIFFUSE MIDLINE GLIOMA

人源化抗CAR抗体影响弥漫性中线胶质瘤中GD2-CAR T细胞的持久应答

2025-11-010
OAAI
Outcomes following CD22 CAR T-cells in B-ALL: a tale of two manufacturing strategies

CD22 CAR T细胞在B-ALL中的治疗效果:两种制造策略的故事

2025-10-020
PRE
The Use and Impact of Patient Support Groups in Hidradenitis Suppurativa Patients
2025-01-290
PRE
MYELOID POPULATIONS MODULATE GD2 CAR T CELL ACTIVITY IN DIFFUSE MIDLINE GLIOMA
2024-11-110
PRE
GLUT1 overexpression in CAR-T cells induces metabolic reprogramming and enhances potency

Car-t细胞中GLUT1过表达诱导代谢重编程并增强效力

2024-10-061
OAAI
CD22-directed CART-cell therapy for large B-cell lymphomas progressing after CD19-directed CART-cell therapy: a dose- finding phase 1 study
LANCET
IF88.5
2024-07-013
OAAI
SEQUENTIAL INTRAVENOUS AND INTRACEREBROVENTRICULAR GD2-CAR T-CELL THERAPY FOR H3K27M-MUTATED DIFFUSE MIDLINE GLIOMAS
2024-06-180
OAAI
CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b results
LEUKEMIA
IF13.4
2024-03-153
OA
Homology-independent targeted insertion (HITI) enables guided CAR knock-in and efficient clinical scale CAR-T cell manufacturing
2023-06-2612
OAAI
Neoantigen-directed therapeutics in the clinic: where are we?
2023-06-0110
OAAI
Inosine endows CAR T cells with features of increased stemness and anti-tumor potency
2023-04-040
PRE
Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy
2022-09-12116
OA
Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy

用于癌症免疫治疗的CAR T细胞的可扩展制造

2021-08-03127
OA
CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial

CD19和CD22双重靶向CAR T细胞治疗复发性或难治性b细胞恶性肿瘤的1期临床试验

2021-07-26360
OAAI
GD2 CAR T-CELLS MEDIATE CLINICAL ACTIVITY AND MANAGEABLE TOXICITY IN CHILDREN AND YOUNG ADULTS WITH H3K27M-MUTATED DIPG AND SPINAL CORD DMG
2021-06-014
OAAI
SINGLE CELL RNA SEQUENCING FROM THE CSF OF SUBJECTS WITH H3K27M+DIPG/DMG TREATED WITH GD2 CAR T-CELLULAR THERAPY
2021-06-013
OAAI
Global analysis of shared T cell specificities in human non-small cell lung cancer enables HLA inference and antigen discovery
IMMUNITY
IF26.3
2021-03-0187
OAAI
Development of CAR T Cells Expressing a Suicide Gene Plus a Chimeric Antigen Receptor Targeting Signaling Lymphocytic-Activation Molecule F7
2021-02-0174
OAAI
Tumor infiltrating lymphocytes (TIL) recognize a unique and diverse number of non-synonymous somatic mutations in patients with metastatic breast cancer
2020-08-150
PRE